NasdaqCM:AKTX

Stock Analysis Report

Executive Summary

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases.

Snowflake

Fundamentals

Worrying balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Akari Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.1%

AKTX

-0.1%

US Pharmaceuticals

1.0%

US Market


1 Year Return

2.2%

AKTX

-6.2%

US Pharmaceuticals

6.7%

US Market

Return vs Industry: AKTX exceeded the US Pharmaceuticals industry which returned -6.2% over the past year.

Return vs Market: AKTX underperformed the US Market which returned 6.7% over the past year.


Share holder returns

AKTXIndustryMarket
7 Day-7.1%-0.1%1.0%
30 Day-4.7%-0.5%-1.8%
90 Day-2.7%-2.6%-1.8%
1 Year2.2%2.2%-3.9%-6.2%9.1%6.7%
3 Year-78.7%-78.7%17.4%9.1%46.1%36.6%
5 Yearn/a28.0%14.5%66.9%48.6%

Price Volatility Vs. Market

How volatile is Akari Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Akari Therapeutics undervalued based on future cash flows and its price relative to the stock market?


In this section, we usually try to help investors determine whether Akari Therapeutics is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Akari Therapeutics has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.


Next Steps

Future Growth

How is Akari Therapeutics expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

66.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Earnings vs Savings Rate: AKTX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: AKTX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: AKTX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: Insufficient data to determine if AKTX's revenue is forecast to grow faster than the US market.

High Growth Revenue: Insufficient data to determine if AKTX's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Estimates


Future Return on Equity

High Future ROE: Insufficient data to determine if AKTX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Akari Therapeutics performed over the past 5 years?

0.2%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: AKTX is unprofitable, but has reduced losses over the past 5 years at a rate of 0.2% per year.

Accelerating Growth: Unable to compare AKTX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: AKTX is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.3%).


Return on Equity

High ROE: AKTX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Return on Assets

ROA vs Industry: AKTX is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: AKTX is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is Akari Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: AKTX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: AKTX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: AKTX is debt free.

Reducing Debt: AKTX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet

Inventory Level: AKTX has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if AKTX's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AKTX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: AKTX has less than a year of cash runway if free cash flow continues to grow at historical rates of 3.8% each year.


Next Steps

Dividend

What is Akari Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.5%markettop25%3.8%industryaverage2.3%forecastin3Yearsn/a

Current dividend yield vs market & industry


Dividend Yield and Payments Analysis

Notable Dividend: Unable to evaluate AKTX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate AKTX's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if AKTX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if AKTX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of AKTX's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Akari Therapeutics's salary, the management and board of directors tenure and is there insider trading?

3.8yrs

Average board tenure


CEO

Clive Richardson (54yo)

1.4yrs

Tenure

US$773,966

Compensation

Mr. Clive Richardson serves as the Chief Executive Officer of Akari Therapeutics, Plc since 2019. Mr. Richardson has been the Chief Operations Officer and Director of Akari Therapeutics, Plc since Septembe ...


CEO Compensation Analysis

Compensation vs. Market: Insufficient data to establish whether Clive's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Clive's compensation has increased whilst the company is unprofitable.


Board Age and Tenure

3.8yrs

Average Tenure

69yo

Average Age

Experienced Board: AKTX's board of directors are considered experienced (3.8 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown


Management Team

  • Ray Prudo (74yo)

    Executive Chairman

    • Tenure: 4.1yrs
    • Compensation: US$318.27k
  • Clive Richardson (54yo)

    COO, CEO & Director

    • Tenure: 1.4yrs
    • Compensation: US$773.97k
  • Miles Nunn

    Chief Scientific Officer

    • Tenure: 0yrs

Board Members

  • Don Williams (60yo)

    Director

    • Tenure: 3.3yrs
    • Compensation: US$78.65k
  • Ray Prudo (74yo)

    Executive Chairman

    • Tenure: 4.1yrs
    • Compensation: US$318.27k
  • Clive Richardson (54yo)

    COO, CEO & Director

    • Tenure: 1.4yrs
    • Compensation: US$773.97k
  • James Hill (73yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$75.66k
  • Stuart Ungar (75yo)

    Director

    • Tenure: 4.1yrs
    • Compensation: US$65.36k
  • David Byrne (59yo)

    Director

    • Tenure: 3.5yrs
    • Compensation: US$65.36k
  • Michael Grissinger (65yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$85.19k
  • Peter Feldschreiber (75yo)

    Director

    • Tenure: 1.8yrs
    • Compensation: US$85.19k

Company Information

Akari Therapeutics, Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Akari Therapeutics, Plc
  • Ticker: AKTX
  • Exchange: NasdaqCM
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$37.144m
  • Shares outstanding: 20.41m
  • Website: https://www.akaritx.com

Number of Employees


Location

  • Akari Therapeutics, Plc
  • 75/76 Wimpole Street
  • London
  • W1G 9RT
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
AKTXNasdaqCM (Nasdaq Capital Market)YesSPON ADR EACH REPR 100 ORDUSUSDJun 2014
CLABDB (Deutsche Boerse AG)YesSPON ADR EACH REPR 100 ORDDEEURJun 2014

Biography

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for a range of rare and orphan autoimmune and inflammatory diseases. Its  ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 03:01
End of Day Share Price2019/10/11 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

© 2018 SIMPLY WALL STREET PTY LTD, COMMUNITY DESIGN 2845206, US DESIGN PATENT #29/544/281, EUROPEAN DESIGN REGISTRATION #2845206, STANDARD & POOR’S FINANCIAL SERVICES LLC. ALL RIGHTS RESERVED.

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Copyright © 2018, Standard & Poor’s Financial Services LLC. Reproduction of S&P Capital IQ in any form is prohibited except with the prior written permission of S&P. S&P does not guarantee the accuracy, adequacy, completeness or availability of any information and is not responsible for any errors or omissions, regardless of the cause or for the results obtained from the use of such information. S&P DISCLAIMS ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE. In no event shall S&P be liable for any direct, indirect, special or consequential damages, costs, expenses, legal fees, or losses (including lost income or lost profit and opportunity costs) in connection with subscriber’s or others’ use of S&P Capital IQ. (2018)